The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

Which Antihypertensive Agents in Chronic Kidney Disease?

Andrew S. Levey, MD; and Katrin Uhlig, MD, MS
[+] Article, Author, and Disclosure Information

From Tufts-New England Medical Center, Boston, MA 02111

Note: Dr. Levey was the Work Group Chair and Dr. Uhlig was the Assistant Director of the Evidence Review Team for the National Kidney Foundation K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (1).

Acknowledgments: The authors thank Sara L. Pressel, MS, Barry R. Davis, MD, PhD, Jeffrey A. Cutler, MD, MPH, and Mahboob Rahman, MD, MS for providing additional data from ALLHAT; Panagiotis Vlagpoulos, MD, Mei Chung, MPH, and Joseph Lau, MD, for assistance in data synthesis; and Rebecca Persson for editorial assistance.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Katrin Uhlig, MD, MS, Division of Nephrology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111; e-mail, kuhlig@tufts-nemc.org.

Current Author Addresses: Drs. Levey and Uhlig: Division of Nephrology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111.

Ann Intern Med. 2006;144(3):213-215. doi:10.7326/0003-4819-144-3-200602070-00011
Text Size: A A A

Hypertension is common in chronic kidney disease and is a risk factor for progressive loss of kidney function and kidney failure, as well as cardiovascular disease (CVD) (12). In this issue, Rahman and colleagues (3) report the outcomes of CVD in a subgroup of patients with chronic kidney disease from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The outcomes of kidney disease in the same subgroup were previously reported (4). These reports are important because 17% of ALLHAT participants had chronic kidney disease, making it the largest study of hypertension treatment in patients with this disorder. In this editorial, we compare Rahman and colleagues' results with those of previous studies in patients with chronic kidney disease that looked at the efficacy of antihypertensive agents that interrupt the renin–angiotensin system.

First Page Preview

View Large
First page PDF preview





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.